Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis
Primary Purpose
Pulmonary Fibrosis
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
oxygen
medical air
Sponsored by
About this trial
This is an interventional supportive care trial for Pulmonary Fibrosis focused on measuring Oxygen therapy
Eligibility Criteria
Inclusion Criteria:
- Pulmonary fibrosis of any cause
- Oxygen saturation => 90% at rest in ambient air, and <88% during walking test
Exclusion Criteria:
- Inability to give consent
- Walking impaired by any condition except pulmonary disease
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
oxygen
medical air
Arm Description
oxygen administered through a nasal cannula at a personalized, fixed flow
Medical air administered through a nasal cannula at the same flow
Outcomes
Primary Outcome Measures
distance walked
recorded by operator
Difference in preference of the two treatments compared to no treatment.
VAS scale
Secondary Outcome Measures
Difference in oxygen saturation level
Digitally recorded
Difference in heart rate
Digitally recorded
Difference in dyspnea at the end of test
VAS
Difference in fatigue at the end of test
VAS
Preference between the two treatments
VAS
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02668029
Brief Title
Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis
Official Title
Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis Normoxemic at Rest Who Desaturate on Exercise
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Siena
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients with pulmonary fibrosis often desaturate on exercise. There are no data showing whether ambulatory oxygen can be useful to improve exercise capacity in this condition. Ambulatory ambulatory oxygen is often denied to these patients based on studies conducted on patients with chronic obstructive pulmonary disease, a completely different condition for physiopathology, prognosis, and response to therapy. We therefore planned a controlled study to verify the usefulness of ambulatory oxygen in patients with pulmonary fibrosis
Detailed Description
Criteria for inclusion: Patients with a diagnosis of pulmonary fibrosis of any kind, with oxygen saturation >90% in ambient air at rest, showing a desaturation <88% during a preliminary 6 minutes walking test Criteria for exclusion: Inability to give consent, age <18 or >85 years, walking problems from causes different from pulmonary disease
Procedure:
In a preliminary session, the flow of oxygen needed to prevent desaturation during walking is established according to a validated protocol Guyatt et al, Am J Respir Crit Care Med 2001,163:,942-946.) Two 6 minutes walking tests are then performed in a corridor, at least 30' apart, during administration of oxygen or medical air, in random order and double blind, at the same pre-determined flow, administered through a nasal cannula connected to a wall outlet (concealed from sight, being in a side rum at about mid distance in the corridor) through a 10 mt plastic tubing. Oxygen saturation and pulse rate are monitored through a dedicated recording oximeter (Minoxy, Cosmed) , whose display is concealed to both the patient and the operator, with an alarm set for oxygen saturation <70%, to stop the test in case severe desaturation would occur Data are then transferred to computer for analysis only after both test are performed. Walked distance is recorded by the operator unaware of treatment.
At the end of each test, a short questionnaire is administered with 10 cm Visual Analogue Scales (VAS) for dyspnoea, fatigue, and preference compared to performing the test without any treatment. At the end of the second test a further scale is submitted, asking about the preference between the two treatments.
Primary outcomes are the distance walked and the difference in preference of the two treatments compared o no treatment. Secondary outcomes are differences in minimal saturation level and maximal pulse rate during the test and in the report of dyspnea and fatigue at the end of the test, and the reported preference between the two treatments.
Statistical analysis to evaluate the effect of the treatment on walking distance, heart frequency and oxygen saturation is performed using generalized linear model with a gaussian family and identity link and including order of treatment as a fixed effect. Parameters evaluated using VAS are analyzed using Koch adaptation of Wilkoxon rank test (Senn SS. Cross-over Trials in Clinical Research, 2nd Edition. Wiley 2002)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Fibrosis
Keywords
Oxygen therapy
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
oxygen
Arm Type
Experimental
Arm Description
oxygen administered through a nasal cannula at a personalized, fixed flow
Arm Title
medical air
Arm Type
Placebo Comparator
Arm Description
Medical air administered through a nasal cannula at the same flow
Intervention Type
Drug
Intervention Name(s)
oxygen
Other Intervention Name(s)
ambulatory oxygen
Intervention Description
information already included in arm/group descriptions.
Intervention Type
Drug
Intervention Name(s)
medical air
Other Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
distance walked
Description
recorded by operator
Time Frame
end of test (6 minutes)
Title
Difference in preference of the two treatments compared to no treatment.
Description
VAS scale
Time Frame
end of test (6 minutes)
Secondary Outcome Measure Information:
Title
Difference in oxygen saturation level
Description
Digitally recorded
Time Frame
Walking test (6 min)
Title
Difference in heart rate
Description
Digitally recorded
Time Frame
Walking test (6 min)
Title
Difference in dyspnea at the end of test
Description
VAS
Time Frame
End of test (6 min)
Title
Difference in fatigue at the end of test
Description
VAS
Time Frame
End of test (6 min)
Title
Preference between the two treatments
Description
VAS
Time Frame
End of both tests (45 min)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pulmonary fibrosis of any cause
Oxygen saturation => 90% at rest in ambient air, and <88% during walking test
Exclusion Criteria:
Inability to give consent
Walking impaired by any condition except pulmonary disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Piersante Sestini, MD
Organizational Affiliation
University of Siena
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
15901604
Citation
Guyatt GH, Nonoyama M, Lacchetti C, Goeree R, McKim D, Heels-Ansdell D, Goldstein R. A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. Am J Respir Crit Care Med. 2005 Sep 1;172(5):573-80. doi: 10.1164/rccm.200412-1692OC. Epub 2005 May 18.
Results Reference
background
Links:
URL
http://eu.wiley.com/WileyCDA/WileyTitle/productCd-0471496537.html
Description
Senn SS. Cross-over Trials in Clinical Research, 2nd Edition. Wiley 2002
Learn more about this trial
Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis
We'll reach out to this number within 24 hrs